Publications by authors named "Tiphaine Goulenok"
Objectives: In this large multicentre study, we aimed to compare the effectiveness of intravenous infliximab vs subcutaneous adalimumab in patients with Takayasu arteritis.
Methods: We conducted a retrospective multicentre study across referral centers in France, Italy, Spain, Armenia, Israel, Japan, Tunisia, and Russia, analyzing biological-targeted therapies in TAK from January 2017 to September 2019.
Results: A total of 135 TAK patients who received adalimumab (n = 34) or infliximab (n = 101) for at least 3 months were included.
Objectives: Mutational dynamics of SARS-CoV-2 in immunocompromised hosts, although well documented, remain a relatively unexplored mechanism. This study aims to compare the viral replication load and genetic diversity of SARS-CoV-2 in immunocompromised patients and non-immunocompromised individuals (NICs) from two major hospitals in Paris from January 2021 to May 2023.
Methods: Cycle threshold (CT) values were measured by TaqPath COVID-19 RT-PCR (Thermo Fisher Scientific).
Background: The PEXIVAS (Plasma exchange and glucocorticoids in severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis) trial showed that a reduced-dose glucocorticoid regimen (redGC) was non-inferior to a standard-dose regimen (standGC) with respect to death or end-stage kidney disease (ESKD) in patients with ANCA-associated vasculitis (AAV). However, the primary endpoint did not include disease progression or relapse, cyclophosphamide was the main induction therapy and rituximab (RTX)-treated patients tended to have a higher risk of death or ESKD with redGC. We aimed to evaluate the real-world use of redGC.
View Article and Find Full Text PDFDosing and route of administration of clindamycin given in combination with rifampicin.
Clin Microbiol Infect
May 2025
Article Synopsis
- The study developed a pharmacokinetic (PK) interaction model for clindamycin when used with rifampicin to assess effective dosing strategies.
- It involved analyzing 518 plasma samples from 124 patients to determine how different administration routes and doses of clindamycin could achieve necessary drug concentrations.
- The findings revealed that rifampicin significantly increased the clearance of clindamycin, rendering oral administration ineffective and suggesting that a higher IV dose of clindamycin is required to treat infections effectively.
Background: Hypereosinophilic syndromes (HES) are a heterogenous group of eosinophilic disorders. To date, only retrospective studies of limited sample-size and/or follow-up duration are available.
Methods: The COHESion study is a national prospective multicenter multidisciplinary cohort recruiting both adults or children with the spectrum of eosinophilic disorders (including reactive HE/HES [HE/HES-R], idiopathic HES [HES-I], lymphocytic HES [HES-L], neoplastic HE/HES [HE/HES-N], HE of unknown significance [HE-US], as well as IgG4-related disease [IgG4RD] or ANCA-negative eosinophilic granulomatosis with polyangiitis [EGPA] overlaps).
Objective: To assess safety of fertility treatments in women with systemic lupus erythematosus (SLE).
Design: Data from the multicentre French observational GR2 (Groupe de Recherche sur la Grossesse et les Maladies Rares) study (2014-ongoing).
Setting: Seventy-six centres in France.
[Human papillomavirus and systemic lupus erythematosus: A systematic review].
Rev Med Interne
March 2025
Article Synopsis
- HPV infections can lead to various cancers, and individuals with systemic lupus are at a higher risk for persistent infections and cervical cancer due to weakened immune systems from treatment.
- Effective prevention strategies include HPV vaccination and regular screening for precancerous lesions, but HPV vaccination coverage among adults with systemic lupus is notably low.
- Both healthcare providers and patients must be educated about the significance of HPV vaccination and the need for proactive screening to better prevent HPV-related cancers in at-risk populations.
HPV Infection and Prevention in Patients With Immune-Mediated Inflammatory Diseases: A Scoping Review.
J Clin Rheumatol
October 2024
Article Synopsis
- HPV infections can cause serious cancers in both men and women, making it a big health issue.
- People with certain immune diseases, like lupus, have a higher chance of getting persistent HPV infections and related problems.
- To help these patients, getting vaccinated and regularly screening for early signs of cancer is very important, but many people still aren’t getting the vaccine.*
Article Synopsis
- Susac syndrome is a rare disease primarily affecting young women, characterized by occlusive microvessel issues in the brain, retina, and inner ear, and lacks established treatment protocols from randomized trials.
- The study investigated the effectiveness of glucocorticoids alone or with other immunosuppressive treatments for preventing relapses in Susac syndrome, and involves a national cohort of patients recruited in France since 2011.
- Data were collected on various health indicators and treatments over a 36-month period to determine the first relapse, involving 64 patients, and the study is registered on ClinicalTrials.gov for transparency.
Introduction: Antiphospholipid syndrome (APS) is a cause of pregnancy morbidity. We aim to determine the frequency of criteria and non-criteria anti-phospholipid (aPL) autoantibodies in patients admitted for unexplained fetal death (UFD), pre-eclampsia (PE) and/or fetal growth restriction (FGR).
Methods: All consecutive patients with UFD, PE and/or FGR followed in the department of Obstetrics, Bichat Hospital, University of Paris, Paris, between January 2019 and December 2021 were screened.
Objectives: Data about hydroxychloroquine (HCQ) levels during pregnancy are sparse. We assessed HCQ whole-blood levels at first trimester of pregnancy as a potential predictor of maternal and obstetric/fetal outcomes in patients with systemic lupus erythematosus (SLE).
Methods: We included pregnant SLE patients enrolled in the prospective GR2 study receiving HCQ, with at least one available first-trimester whole-blood HCQ assay.
Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry.
Ann Rheum Dis
October 2024
Objectives: To investigate the frequency and factors associated with disease flare following vaccination against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal diseases (I-RMDs).
Methods: Data from the European Alliance of Associations for Rheumatology Coronavirus Vaccine physician-reported registry were used. Factors associated with flare in patients with I-RMDs were investigated using multivariable logistic regression adjusted for demographic and clinical factors.
Background: Adverse pregnancy outcomes in women with primary Sjögren's syndrome have only been evaluated retrospectively using heterogeneous methods and with contradictory results. We aimed to describe adverse pregnancy, delivery, and birth outcome risks in pregnant women with primary Sjögren's syndrome compared with those of a matched general population in France, and to identify factors predictive of disease flares or adverse pregnancy outcomes.
Methods: We conducted a multicentre, prospective, cohort study in France using the GR2 (Groupe de Recherche sur la Grossesse et les Maladies Rares) registry.
Article Synopsis
- Nonreversible hearing loss (HL) is a significant issue for patients with Susac syndrome (SuS), prompting a study to identify risk factors associated with HL in these individuals.* -
- The CARESS study involved 36 patients diagnosed with SuS, revealing that 52.8% experienced severe HL after a median follow-up of about 52 months, with many showing cochleovestibular involvement at diagnosis.* -
- The study concluded that the use of immunosuppressive (IS) drugs at diagnosis may lower the odds of developing severe HL, suggesting these drugs should be regularly considered in SuS treatment.*
Incidence, risk factors and treatment of central nervous system immune reconstitution inflammatory syndrome in non-HIV patients with tuberculous meningitis: a multicentre observational study.
Intern Med J
May 2024
Background: Immune reconstitution inflammatory syndrome (IRIS) affecting the central nervous system (CNS) is associated with poor outcomes.
Aims: To report on risk factors for CNS-IRIS following tuberculous meningitis (TBM) in HIV-negative patients.
Methods: In this retrospective multicentre study, all HIV-negative adult patients admitted between 2003 and 2021 with microbiologically proven TBM were included.
Article Synopsis
- Immunocompromised individuals tend to experience longer SARS-CoV-2 infections, increasing the chances for new mutations, especially in the spike protein, which is important for vaccines.
- A study in Paris analyzed samples from 444 immunocompromised patients and 234 healthcare workers, finding greater genetic diversity of the virus in the immunocompromised group.
- The research indicated that mutations in the viruses from immunocompromised patients contributed to the evolution of new variants, suggesting potential concerns for immune response and severity of future infections.
Introduction: Complement activation emerged as a key actor of anti-neutrophil cytoplasmic antibodies-associated vasculitis (AAV). Whether serum levels of C3 (sC3) or C3 kidney deposition may help to refine the prognosis of AAV remains elusive.
Methods: Retrospective multicentric study that included 154 patients with a first flare of AAV and sC3 (n = 143) or C3 kidney staining (n = 95) available at diagnosis.
Article Synopsis
- A study compared two ways of giving a medicine called tocilizumab to patients with a disease called Takayasu arteritis (TAK).
- They looked at 109 patients from different countries and found that both methods worked similarly well after 6 months, with about 69% showing improvement.
- However, patients who got tocilizumab as a shot under the skin had a higher chance of getting worse again compared to those who received it through an IV.